Read by QxMD icon Read

neo-adjuvant chemotherapy

Martin David Forster, Michael-John Devlin
Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer globally and commonly presents with locally advanced disease, which has a recurrence rate of around 50% despite aggressive multi-modality treatment involving surgery, radiotherapy and chemotherapy or EGFR inhibition where appropriate. As understanding of the underlying cancer biology and the complex interactions within the tumor microenvironment improves, there is gathering interest in and evidence for the role of immunomodulating agents in the management of HNSCC...
2018: Frontiers in Oncology
Danijela Golo, Jasna But-Hadzic, Franc Anderluh, Erik Brecelj, Ibrahim Edhemovic, Ana Jeromen, Mirko Omejc, Irena Oblak, Ajra Secerov-Ermenc, Vaneja Velenik
Background The purpose of the study was to improve treatment efficacy for locally advanced rectal cancer (LARC) by shifting half of adjuvant chemotherapy preoperatively to one induction and two consolidation cycles. Patients and methods Between October 2011 and April 2013, 66 patients with LARC were treated with one induction chemotherapy cycle followed by chemoradiotherapy (CRT), two consolidation cycles, surgery and three adjuvant capecitabine cycles. Radiation doses were 50.4 Gy for T2-3 and 54 Gy for T4 tumours in 1...
September 11, 2018: Radiology and Oncology
Claudio Fiorino, Calogero Gumina, Paolo Passoni, Anna Palmisano, Sara Broggi, Giovanni M Cattaneo, Alessandra Di Chiara, Antonio Esposito, Martina Mori, Roberta Raso, Monica Ronzoni, Riccardo Rosati, Najla Slim, Francesco De Cobelli, Riccardo Calandrino, Nadia G Di Muzio
PURPOSE: Introducing a radiobiological index based on early tumor regression during neo-adjuvant radio-chemotherapy (RCT, including oxaliplatin) of rectal adenocarcinoma and testing its discriminative power in predicting the tumor response. METHODS: Seventy-four patients were treated with Helical Tomotherapy following an adaptive (ART) protocol (41.4 Gy/18 fr, 2.3 Gy/fr) delivering a simultaneous integrated boost on the residual tumor in the last 6 fractions up to 45...
September 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Duniya Mosly, Arran Turnbull, Andrew Sims, Carol Ward, Simon Langdon
Ongoing clinical and research efforts seek to optimise the use of endocrine therapy in the treatment of breast cancer. Accurate biomarkers are needed that predict response for individual patients. The presence of the estrogen receptor (ER) as the direct (for tamoxifen and fulvestrant) or indirect (for aromatase inhibitors) target molecule for endocrine therapy remains the foremost biomarker and determinant of response. However, ER expression only poorly predicts outcome and further indicators of response or resistance are required...
August 30, 2018: World Journal of Experimental Medicine
Jenny Rystedt, Bobby Tingstedt, Christoph Ansorge, Johan Nilsson, Bodil Andersson
BACKGROUND: Pancreatoduodenectomy is associated with a high risk of complications. The aim was to identify preoperative risk factors for major intraoperative bleeding. METHODS: Patients registered for pancreatoduodenectomy in the Swedish National Pancreatic and Periampullary Cancer Registry, 2011 to 2016, were included. Major intraoperative bleeding was defined as ≥1000 ml. Univariable and multivariable analysis of preoperative parameters were performed. RESULTS: In total, 1864 patients were included...
August 28, 2018: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
J V Groen, B G Sibinga Mulder, E van Eycken, Z Valerianova, J M Borras, L G M van der Geest, G Capretti, A Schlesinger-Raab, M Primic-Zakelj, A Ryzhov, C J H van de Velde, B A Bonsing, E Bastiaannet, J S D Mieog
BACKGROUND: The EUropean REgistration of Cancer CAre (EURECCA) consortium aims to investigate differences in treatment and to improve cancer care through Europe. The purpose of this study was to compare neo- and adjuvant chemotherapy (ACT) and outcome after tumor resection for pancreatic adenocarcinoma stage I and II in the EURECCA Pancreas consortium. METHODS: The eight, collaborating national, regional, and single-center partners shared their anonymized dataset...
August 27, 2018: Annals of Surgical Oncology
Omar Najim, Yanina Dockx, Ivan Huyghe, Tim van den Wyngaert, Konstantinos Papadimitriou, Wiebren A A Tjalma, Manon T Huizing
OBJECTIVE: A sentinel Node (SN) has replaced axillary lymph node dissection (ALND) in patients with clinically node negative axilla (cN0). SN after Neo-adjuvant chemotherapy (NACT) is feasible but not accurate in clinically node positive (cN1-3) patients. The goal of this study is to determine the negative predictive value (NPV) of SN in cN0 breast cancer after NACT. A secondary endpoint is to determine if ALND can be avoided after NACT regardless of the pre-treatment clinical staging of the axilla, in case of a normalization of the 18 F-fluoro-2-deoxy-glucose positron emission tomography scan (PET-CT scan)...
June 28, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
Marie Christine Hupe, Axel S Merseburger, Maike de Wit, Heidrun Rexer, Jürgen E Gschwend, Susanne Krege
BACKGROUND:  In 2016, the first German guideline for bladder cancer was introduced. This survey evaluates current management of bladder cancer in Germany, focusing on systemic therapies and compares this to the guidelines. MATERIAL AND METHODS:  More than 4000 urologists and oncologists in Germany received a questionnaire assessing surgical and systemic therapeutic management of bladder cancer. We received 278 evaluable responses. RESULTS:  This is the largest nationwide survey evaluating current bladder cancer management in Germany...
August 2018: Aktuelle Urologie
Yuki Kohada, Tetsutaro Hayashi, Keisuke Goto, Kohei Kobatake, Hamidreza Abdi, Yukiko Honda, Kazuhiro Sentani, Shogo Inoue, Jun Teishima, Kazuo Awai, Wataru Yasui, Akio Matsubara
Background: To improve the prediction of outcomes in patients who will undergo radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), we examined the preoperative prognostic factors and established a risk classification model. Methods: A total of 148 patients who underwent RNU without history of neo-adjuvant chemotherapy between 1999 and 2016 in Hiroshima University Hospital were retrospectively reviewed. Associations between preoperative/clinicopathological factors and outcomes including cancer-specific survival (CSS) and recurrence-free survival (RFS) were assessed...
September 1, 2018: Japanese Journal of Clinical Oncology
Dominique Reed, Komal Raina, Rajesh Agarwal
Prostate cancer (PCa) is the most frequently diagnosed malignancy and second leading cause of cancer mortality in American males. Notably, men of African descent in the United States and Caribbean have the highest PCa mortality rates compared to men with European ancestry. Although current therapeutics are quite potent and effective, disease resistance, progression to metastasis, therapy-associated toxicities and efficacy-related issues in diverse populations develop over time. Thus, non-toxic and efficacious therapeutic strategies are needed to address these major obstacles for the clinical treatment and management of PCa...
2018: NPJ Precision Oncology
Lilian Schwarz, Dewi Vernerey, Jean-Baptiste Bachet, Jean-Jacques Tuech, Fabienne Portales, Pierre Michel, Antonio Sa Cunha
BACKGROUND: At time of diagnosis, less than 10% of patients with pancreatic adenocarcinomas (PDAC) are considered to be immediately operable (i.e. resectable). Considering their poor overall survival (OS), only tumours without vascular invasion (NCCN 2017) should be considered for resection, i.e. those for which resection with disease-free margins (R0) is theoretically possible in absence of presurgery treatment. With regard to high R1 rates and undetectable locoregional and/or metastatic spreading prior to surgery explain (at least in part) the observed 1-year relapse and mortality rates of 50 and 25%, respectively...
July 24, 2018: BMC Cancer
Reva K Basho, Heather L McArthur
The development of human epidermal growth factor 2 (HER2)-directed therapy has resulted in significant improvement in outcomes for patients with early-stage HER2-overexpressing (HER2+) breast cancer. In recent years, newer HER2-directed agents and novel treatment strategies have been developed with ongoing improvements in overall outcomes. However, with the addition of newer agents, there is an increasing need to risk stratify patients to maximize efficacy and minimize toxicity of treatment. De-escalation of therapy with the potential to shorten the duration of adjuvant therapy and minimize chemotherapy administration in patients with favorable disease can be considered...
2018: Therapeutic Advances in Medical Oncology
J Th C M de Kruif, M B Scholtens, J van der Rijt, M R de Boer, M M G A van den Berg, Y C de Vries, R M Winkels, M Visser, E Kampman, M J Westerman
PURPOSE: Dutch Health care professionals (HCPs) provide little information concerning health risks associated with weight gain during chemotherapy for breast cancer. Women with breast cancer have specified the need for more information on nutrition and physical activity to deal with weight gain. The aims of this study were to assess the perceptions of Dutch HCPs on weight gain during chemotherapy and in addition evaluate whether and what kind of information on dietary intake and physical activity HCPs provide to prevent/treat weight gain during (neo)adjuvant chemotherapy...
July 19, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Alessandro Gronchi
No abstract text is available yet for this article.
September 2018: European Journal of Cancer
Hiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, Yasuhiro Okumura, Toshimi Takano, Eriko Tokunaga, Tsuyoshi Saito, Yasuaki Sagara, Kosuke Yamazaki, Yoshihiro Kawaguchi, Tecchuu Lee, Shinji Ozaki, Kazuhiko Yamagami, Naohito Yamamoto, Katsumasa Kuroi, Hirofumi Suwa, Shoichiro Ohtani, Toshikazu Ito, Shinji Yasuno, Satoshi Morita, Shinji Ohno, Masakazu Toi
Background: There are little data on the usefulness of trastuzumab (TZM) retreatment as the first-line treatment for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer recurrence after perioperative treatment with TZM. Aim: To clarify the outcome and safety of TZM retreatment in patients with recurrent HER2-positive breast cancer. Method: An observational study was conducted on patients who relapsed after primary systemic therapy with TZM using the central registration system...
2018: Breast Cancer: Basic and Clinical Research
M Timmermans, M A van der Aa, R I Lalisang, P O Witteveen, K K Van de Vijver, R F Kruitwagen, G S Sonke
OBJECTIVE: Treatment for advanced epithelial ovarian cancer (EOC) consists of debulking surgery and (neo)adjuvant platinum-based chemotherapy. The aim of this study was to evaluate whether the time from surgery to adjuvant chemotherapy (TTC) was associated with clinical outcome. METHODS: We identified all Dutch patients who received optimal or complete debulking surgery for primary EOC (FIGO IIb-IV) between 2008 and 2015 from the Netherlands Cancer Registry. TTC was divided into three groups based on the interquartile range (IQR)...
September 2018: Gynecologic Oncology
Rossella Loria, Valentina Laquintana, Giulia Bon, Daniela Trisciuoglio, Roberta Frapolli, Renato Covello, Carla Azzurra Amoreo, Virginia Ferraresi, Carmine Zoccali, Mariangela Novello, Donatella Del Bufalo, Michele Milella, Roberto Biagini, Maurizio D'Incalci, Rita Falcioni
Although the medical treatments of sarcoma have evolved in the last years, a significant portion of patients develops recurrence after therapies suggesting the need to identify novel targets to improve the treatments. By the use of patient-derived and established cell lines from liposarcoma, as well as specimens from patient biopsies, we found that HMGA1 is involved in the progression of dedifferentiated and myxoid liposarcoma. The immunohistochemical and RT-PCR analyses of 68 liposarcoma specimens revealed a significant high expression of HMGA1, at the protein and RNA levels, both in myxoid and dedifferentiated liposarcoma subtypes compared with differentiated ones...
July 6, 2018: Oncogene
Andrew Robinson, Osama Souied, A Brianne Bota, Nathalie Levasseur, Carol Stober, John Hilton, Dalia Kamel, Brian Hutton, Lisa Vandermeer, Sasha Mazzarello, Anil A Joy, Dean Fergusson, Sheryl McDiarmid, Mathew McInnes, Risa Shorr, Mark Clemons
IMPORTANCE: Systemic chemotherapy can be administered either through a peripheral vein (IV), or centrally through peripherally inserted central catheter (PICC), totally implanted vascular access devices (PORTs) or tunnelled cuffed catheters. Despite the widespread use of systemic chemotherapy in patients with breast cancer, the optimal choice of vascular access is unknown. OBJECTIVE: This systematic review evaluated complication rates and patient satisfaction with different access strategies for administering neo/adjuvant chemotherapy for breast cancer...
October 2018: Breast Cancer Research and Treatment
Yasuaki Sagara, Masahiro Takada, Yasuyo Ohi, Shoichiro Ohtani, Sasagu Kurozumi, Kenichi Inoue, Yoshimasa Kosaka, Masaya Hattori, Toshinari Yamashita, Shintaro Takao, Nobuaki Sato, Hiroji Iwata, Masafumi Kurosumi, Masakazu Toi
PURPOSE: While human epidermal growth factor receptor 2 (HER2) target therapies have significantly improved the prognosis of patients with HER2-enriched breast cancer, differing clinical benefits and gene expression analyses suggest a divergent HER2 subgroup. We aimed to investigate whether the basal HER2 subtype of breast cancer has distinguished characteristics. METHODS: We performed a substudy by using data from a retrospective multi-institutional cohort of JBCRG-C03...
October 2018: Breast Cancer Research and Treatment
J Wei, T Yao, Y Wang, L Li, C Pan, N Zhang
AIM: To study the prognostic factors of gastric cancer (GC) patients who were classified with stage III disease according to the newest TNM classification. METHODS: This study retrospectively enrolled 279 patients who underwent radical gastrectomy from January 2012 to December 2014 at our hospital and who were diagnosed with stage III GC according to the new 8th edition of the TNM classification. The patient data that were collected included age, sex, pathological parameters, survival, lymph node ratio, neo-adjuvant chemotherapy with oxaliplatin and S-1, and operation type...
July 2, 2018: Clinical & Translational Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"